DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML).
The interventions involved in this study are:
-Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)
A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion cell vaccine versus observation in patients who achieve a chemotherapy-induced remission
- ClinicalTrials.gov Identifier: NCT03059485
- Protocol Number: 16-593
- Principal Investigator: Jacalyn Rosenblatt
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required